Last edition
News about "GSK Strengthens Global Respiratory Pipeline"
NMPA Nod for GSK's Exdensur Boosts Biologics Manufacturing Momentum
GSK plc has received approval from China’s National Medical Products Administration (NMPA) for Exdensur (depemokimab) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in patients aged 12 years and above.
GSK Strengthens Global Respiratory Pipeline | 31/03/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members